Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2013
Accounting Standards: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional segments in biopharmaceuticals (haemophilia, growth hormone, hormone replacement). The company operates in over 180 countries with approximately 38,000 employees. The 2013 reporting period includes a stock split of B shares effective January 2, 2014, changing the nominal value from DKK 1 to DKK 0.20; comparative figures have been restated accordingly.
Key Financial Metrics (2013)
| Metric | 2013 (DKK Millions) | 2012 (DKK Millions) |
|---|---|---|
| Net Sales | 83,572 | 78,026 |
| Operating Profit | 31,493 | 29,474 |
| Net Profit | 25,184 | 21,432 |
| Operating Margin | 37.7% | 37.8% |
| Net Profit Margin | 30.1% | 27.5% |
| Free Cash Flow | 22,358 | 18,645 |
| Net Cash from Operating Activities | 25,942 | 22,214 |
| Total Assets | 70,337 | 65,669 |
| Net Assets (Equity) | 42,569 | 40,632 |
| Long-term Debt | 0 | 0 |
| Current Debt | 215 | 500 |
| Financial Resources (Cash + Bonds + Credit Facilities) | 19,103 | 20,454 |
Per Share Data (Restated):
- Earnings per Share (EPS): DKK 9.40 (2013) vs DKK 7.82 (2012)
- Proposed Dividend per Share: DKK 4.50 (2013) vs DKK 3.60 (2012)
- Payout Ratio: 47.1% (2013) vs 45.3% (2012)
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 7.1% to DKK 83.6 billion, driven by volume growth in diabetes care and biopharmaceuticals, partially offset by currency fluctuations.
- Profitability: Operating profit rose 6.9% to DKK 31.5 billion. Net profit increased 17.5% to DKK 25.2 billion, aided by a lower effective tax rate and improved operating leverage.
- Cash Flow: Free cash flow improved significantly by 20% to DKK 22.4 billion, reflecting strong operating performance and disciplined capital expenditure management.
- Debt Position: The company maintained a debt-free status regarding long-term loans, having repaid all such loans in 2012. Current debt decreased to DKK 215 million.
- Share Repurchases: The company completed a DKK 14 billion share repurchase program in January 2014, purchasing 67.6 million shares during 2013.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects R&D spending to remain at 13-15% of sales. Capital expenditure for 2014 is projected at approximately DKK 3.5 billion, focused on expanding production for GLP-1, devices, and insulin filling capacity in the US, France, and Russia.
Key Risks and Contingencies
- Patent Expirations: Key products face patent expirations. NovoLog/NovoRapid compound patents expired in Europe (2011) and Japan (2010), though formulation patents extend protection to 2017. Prandin/NovoNorm faces generic competition in Europe and the US following a 2013 court ruling invalidating a combination patent.
- Regulatory: The company received an FDA Warning Letter in December 2012 regarding a Danish facility; violations were addressed satisfactorily by January 2014 with no expected impact on current products.
- Geopolitical: The company conducts business in Iran, Syria, Sudan, and Cuba. Gross revenue from Iran-related transactions in 2013 did not exceed DKK 400 million. Transactions are conducted via non-sanctioned banks.
- Market Conditions: Pricing pressure due to austerity measures in key markets (China, Europe) and competitive pressure in Japan and International Operations.
Unusual Items
No significant unusual items were reported in the 2013 financial statements. The company utilizes asset securitization programs in Japan and factoring in Italy and Spain to manage liquidity, which are non-recourse off-balance sheet arrangements.
Investor Verification Checklist
- Patent Cliff Impact: Verify the actual sales erosion of Prandin/NovoNorm in the US and Europe due to generic entry following the June 2013 court decision.
- Regulatory Compliance: Confirm the status of the FDA Warning Letter resolution and any ongoing inspections of the Danish aseptic filling facility.
- Iran Transactions: Review the specific nature and volume of transactions with Government of Iran (GOI) entities to ensure compliance with US sanctions regulations.
- Share Repurchase Execution: Confirm the final cancellation of treasury shares following the completion of the DKK 14 billion buyback program.
- R&D Pipeline: Monitor the regulatory approval status of key pipeline candidates, specifically Liraglutide 3mg for obesity and IDegLira, which were in Phase 3 or filing stages.